New PharmGKB VIP Summary: NAT2
N-acetyltransferase enzymes (NAT1 and NAT2) are involved in the metabolism and detoxification of xenobiotics. NAT2 is predominantly expressed in the liver and has a role in the metabolism of numerous therapeutic drugs including caffeine and BiDil. Genetic variants in the NAT2 gene result in a slow, intermediate or rapid acetylator phenotype.
Numerous studies have reported an association between slow acetylator status (based on NAT2 genotype) and anti-TB drug-induced hepatotoxicity, though other studies find no such association. Similarly, the association between NAT2 genetic variants and side effects of co-trimoxazole or hydralazine is also unclear. <!-- /* Font Definitions */ @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:Cambria; mso-fareast-font-family:Cambria; mso-bidi-font-family:Cambria;} @page Section1 {size:8.5in 11.0in; margin:1.0in 1.25in 1.0in 1.25in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.Section1 {page:Section1;} -->
The PharmGKB VIP Summary for NAT2 discusses these contradictions and links to summaries of important NAT2 variants underlying these PGx associations.